SKILLMAN, N.J., Feb. 21, 2012 /PRNewswire/ -- ConvaTec, a world-leading developer and marketer of innovative medical technologies for community and hospital care, today announces that Ken Berger will assume the position of CEO, ConvaTec, and will be appointed to the ConvaTec Board of Directors.
Berger joins ConvaTec from Thermo Fisher Scientific where he spent the last ten years, most recently as Senior Vice President and Group President of the Specialty Diagnostics Group, a global $2 billion high-value diagnostics business. "We are excited to have Ken take over the helm of ConvaTec," said Toni Weitzberg, Chairman of the Board of Directors for ConvaTec. "His track record of building highly profitable businesses, combined with diverse global experience and a history of building strong leadership teams is well suited to take ConvaTec to the next level of performance excellence."
"I am pleased to work with Nordic Capital and Avista Capital Partners as CEO of ConvaTec," said Berger, "and I look forward to working with the ConvaTec team to realize the incredible potential of this business."
This appointment follows the mutual agreement between David I. Johnson and the ConvaTec Board of Directors that he will step down as CEO, effective March 5, 2012. "Dave successfully managed the carve-out from Bristol Myers Squibb Co. and created an independent global company with a strong platform for growth," stated Weitzberg. "The Board thanks him for his service in leading ConvaTec over the past six years, and for his dedication to the Company for over twelve years."
"I am proud to leave this fine organization with a strengthened financial foundation, renewed growth momentum; and of course, a continued commitment to the company mission," said Johnson. "I am confident that the entire organization is ready to take ConvaTec to even greater heights."
Over the next sixty days, Johnson will work with the Board and his success
Copyright©2010 PR Newswire.
All rights reserved